Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product
October 25, 2019
Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing
September 18, 2019
Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders
August 27, 2019
Spark Therapeutics Enters into Definitive Merger Agreement with Roche
February 25, 2019
Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress
February 19, 2019
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights
February 12, 2019
Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™
January 31, 2019
Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.
January 24, 2019
Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference
January 2, 2019